HT-2157 (former development code SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin.

Blocking this receptor with HT-2157 produced increased serotonin release,[1] as well as producing antidepressant and anxiolytic effects in animal studies,[2] and it was also being researched for treatment of cognitive dysfunction.

[3] All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.

This article about an anxiolytic is a stub.

You can help Wikipedia by expanding it.